PROTEOME IN HIGH TECH CONTRA-DEAL WITH AGILENT
May 29th 2008 23:30
Wednesday May 28, 2008
Daily news on ASX-listed biotechnology companies
* ASX, BIOTECHS DOWN: PHARMAXIS UP 8%; TISSUE THERAPIES DOWN 8%
* PROTEOME IN HIGH TECH CONTRA-DEAL WITH AGILENT
* FERMISCAN TO PAY $5.5m FOR SYDNEY BREAST CLINIC
* CBIO IN NOVO NORDISK DEAL; VIRALYTICS DIVESTS PASSIVE SHARES
* BIOTA, GSK TRIAL POSTPONED
* AGENIX’S NEIL LEGGETT REPLACED AS COMPANY SECRETARY
* STEM CELL GRANTS CEO DR ALASTAIR RIDDELL 680k OPTIONS
* XENOME APPOINTS ADAM DAY CFO
THE MARKET
Nine of the Biotech Daily Top 40 stocks were up, 15 fell, 14 traded unchanged and two were untraded.
Pharmaxis was best, up 11 cents or 7.56 percent to $1.565 on moderate volumes, followed by Cathrx up six cents or 6.38 percent to $1.00.
Tissue Therapies led the falls, down one cent or 8.33 percent to 11 cents on small volumes, followed by Peplin down four cents or 8.16 percent to 45 cents.
subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
PROTEOME
Proteome has licenced its Glycomiq software and Glycosuite DB database to Agilent Technologies in return for sophisticated equipment and potential royalties.
Proteome said Agilent had the rights to further develop and sell Glycomiq and Glycosuite DB, as well as use the products for internal development purposes.
Proteome Systems will receive a high-performance Agilent mass spectrometer and HPLC-Chip Cube (a nanospray high performance liquid chromatography for mass spectrometry) for the company’s biomarker discovery platform, in addition to a royalty stream from any product sales made by Agilent.
Proteome said Agilent was “the world’s premier measurement company and a technology leader in communications, electronics, life sciences and chemical analysis”.
Proteome said Agilent recognized its expertise in glycomics and glycoprotein-based biomarker research and the two companies had collaborated over the past three years to develop new workflow solutions for mass spectrometric analysis of glycoproteins (proteins with sugars).
The company said the agreement was the outcome of those joint activities.
Proteome chief executive officer Dr Jenny Harry said diseases including cancer, arthritis and influenza caused changes to the sugars that are attached to proteins and the changes could be “highly accurate and powerful diagnostic biomarkers of disease”.
She said Proteome owned an extensive database (Glycosuite DB) of curated glycoprotein sugar structures and a suite of bioinformatic tools “which enable the interpretation of mass spectrometric data generated for these sugar structures”.
She said the Agilent mass spectrometer and HPLC-Chip Cube would “enable rapid and sensitive analyses of complex glycoproteins, providing greater efficiencies to our biomarker discovery and development programs”.
Proteome was unchanged at 13 cents.
subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
| 47 |
| Vote |
Add To: 
subscribe to this blog